Advertisement

AVEO Oncology (Nasdaq: AVEO) and its Japanese partner Astellas Pharma, have submitted kidney cancer drug candidate tivozanib to the U.S. Food and Drug Administration.

In advance of the submission, Cambridge, Mass.-based AVEO has been beefing up its staff, and in May, inked a deal for a new, larger headquarters.

If approved, it would be the first drug on the market developed by AVEO. The companies are seeking approval for treatment of patients with advanced renal cell carcinoma.

Advertisement
Advertisement